Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03087019 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03087019 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants.
The verdict
NCT03087019, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This research study is studying immunotherapy with or without radiation therapy as a possible treatment for adenoid cystic carcinoma. The immunotherapy involved in this study is: * Pembrolizumab (MK-3475 or KEYTRUDA).
Interventions
- DRUG Pembrolizumab
- RADIATION Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-04-25 |
| Est. Completion | 2020-08-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03087019
The ClinicalTrials.gov registry entry for NCT03087019 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT03087019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03087019 about?
NCT03087019 is a clinical study titled "Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma". This research study is studying immunotherapy with or without radiation therapy as a possible treatment for adenoid cystic carcinoma. The immunotherapy involved in this study is: * Pembrolizumab (MK-3475 or KEYTRUDA).
What is the current status of trial NCT03087019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2017-04-25. Estimated completion is 2020-08-04.
What interventions are being tested in trial NCT03087019?
The interventions under investigation include: Pembrolizumab (DRUG), Radiation (RADIATION).
Who is sponsoring clinical trial NCT03087019?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.